Sandoz to buy eye drug Cimerli in $170 million deal
ZURICH (Reuters) -Sandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for $170 million. The drug is interchangeable with Lucentis, a product marketed by Roche’s Genentech in the United States and by Novartis in the rest of the world, for all approved …
Sandoz to buy eye drug Cimerli in $170 million deal Read More »